Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products

Medical Science Monitor

Volumn 10, Issue 6, 2004, Pages

  Dzierzewicz, Zofia ^a   Cwalina, Beata ^a   Wȩglarz, Ludmila ^a   Wiśniowska, Beata ^a   Szczerba, Joanna ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

5 aminosalicylic acid; Biotransformation; Desulfovibrio desulfuricans; Intestinal strains; Sulfapyridine; Sulfasalazine; Susceptibility

Indexed keywords

MESALAZINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; BILIARY CIRRHOSIS; CHEMICAL BOND; COLON ADENOMA; COLON DIVERTICULOSIS; CROHN DISEASE; DESULFOVIBRIO; DRUG TRANSFORMATION; FECES; GROWTH INHIBITION; INFLAMMATORY DISEASE; INTESTINE BIOPSY; INTESTINE FLORA; IRRITABLE COLON; LARGE INTESTINE; NONHUMAN; ULCERATIVE COLITIS;

BIOTRANSFORMATION; CELL DIVISION; DESULFOVIBRIO DESULFURICANS; DRUG RESISTANCE, BACTERIAL; HUMANS; INTESTINES; MESALAMINE; SULFAPYRIDINE; SULFASALAZINE;

EID: 3042817607     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Beerens H, Romond C: Sulfate-reducing bacteria in human feces. Am J Clin Nutr, 1977; 30: 1770-7
2. Dzierżewicz Z, Cwalina B, Gawlik B, Wilczok T, Gonciarz Z. Isolation and evaluation of susceptibility to sulphasalazine of Desulfovibrio desulfuricans strains from the human digestive tract. Acta Microbiol. Pol, 1997; 46: 175-87
3. Dzierżewicz Z, Cwalina B, Jaworska-Kik M, Wěglarz L, Wilczok T. Susceptibility to antibiotics and biochemical properties of Desulfovibrio desulfuricans strains. Acta Pol. Pharm. Drug Res, 2001; 58: 439-44
4. Dzierżewicz Z, Cwalina B, Kurkiewicz S, Chodurek E, Wilczok T. Intraspecies variability of cellular fatty acids among soil and intestinal strains of Desulfovibrio desulfuricans. Appl. Environ. Microbiol, 1996; 62: 3360-65
5. Dzierżewicz Z, Gawlik B, Cwalina B, Gonciarz K, Ziół kowski G, Gonciarz Z, Wilczok T. Activity of sulphate-reducing bacteria in the human digestion tract. Bull. Pol. Acad. Sci, 1994; 42: 171-6
6. Gibson GR, Cummings JH, Macfarlane GT. Growth and activities of sulphate-reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol. Ecol. 1991; 86: 103-12
7. Gibson GR, Macfarlane GT, Cummings JH. Occurrence of sulphate-reducing bacteria in human faeces and the relationship of dissimilatory sulphate reduction to methanogenesis in the large gut. J. Appl. Bacteriol, 1988; 65: 103-11
8. Pitcher M C L, Beatty E R, Cummings J H. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut, 2000; 46: 64-72
9. Zinkevich V, Beech I B. Screening of sulphate-reducing bacteria in colonoscopy samples from healthy and colitic human gut mucosa. FEMS Microbiol. Ecol, 2000; 34: 147-55
10. Postgate J R. The Sulfate-Reducing Bacteria, Cambridge University Press, Cambridge; 1984
11. Pitcher M C L, Cummings J H. Hydrogen sulphide: a bacterial toxin in ulcerative colitis? Gut, 1996; 39: 1-4
12. Loubinoux J, Mory F, Pereira L A C, Le Faou A E. Bacteremia caused by a strain of Desulfovibrio related to the provisionally named Desulfovibrio fairfieldensis. J. Clin. Microbiol, 2000; 38: 931-4
13. Lozniewski A, Maurer P, Schuhmacher H, Carlier J P, Mory F. First isolation of Desulfovibrio sp. as part of a polymicrobial infection from a brain abscess. Eur. J. Clin. Microbiol. Infect. Dis, 1999; 18: 602-3
14. Schoenborn L, Abdollahi H, Tee W, Dyall-Smith M, Janssen P H. A member of the delta subgroup of proteobacteria from pyogenic liver abscess is a typical sulfate reducer of the genus Desulfovibrio. J. Clin. Microbiol, 2001; 39: 789-90
15. Azad Khan A K, Piris J, Truelove S C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet, 1977; 2: 892-5
16. Hazenberg M P, Bakker M, Both-Patoir H C, Ruseler-van Embden J G H, Schōder A M. Effect of sulphasalazine on human intestinal flora. J. App. Bacteriol, 1982; 52: 103-7
17. Peppercorn M A. Advances in drug therapy for inflammatory bowel disease. Ann. Intern. Med, 1990; 110: 353-6
18. Van Hees P A M, Bekker J H, Van Tongeren J H M. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the therapeutic active moiety of sulphasalazine. Gut, 1980; 21: 632-5
19. West B, Lendrum R, Walker G. Effect of sulphasalazine (salazopyrin) on faecal flora in patients with inflammatory bowel disease. Gut, 1974; 15: 960-5
20. Dzieriewicz Z. Intraspecies variability of the metabolic activity of Desulfovibrio desulfuricans, and their role in biotransformation of sulphasalazine (in Polish). Ann. Acad. Med. Siles, 1996; 1-185
21. Dzierżewicz Z, Cwalina B, Kośmierz D, Gawlik B. Desulfovibrio desulfuricans intestinal bacteria can induce the therapeutic efficacy of sulphasalazine. Acta Pol. Pharm. Drug Res, 2000; 57: 23-5
22. Widel F, Pfenning N. Dissimilatory sulfate- or sulphur-reducing bacteria. In: Bergey's Manual of Systematic Bacteriology (Krieg N.R. and Holt J.G, Eds), Vol. 1, Williams and Wilkins, Baltimore; 1984: 663-79
23. Dzierżewicz Z, Szczerba J, Wȩglarz L, Swiatkowska L. Jasińska D, Wilczok T. Intraspecies variability of Desulfovibrio desulfuricans strains determined by the genetic profiles. FEMS Microbiol. Lett, 2003: 219: 69-74
24. Singleton P. Bacteria in biology, bacteriology and medicine (in Polish), PWN, Warszawa, 2000
25. Dzierżewicz Z, Cwalina B, Chodurek E, Wilczok T. The relationship between microbial metabolic activity and biocorrosion of carbon steel, Res. Microbiol, 1997; 148: 785-93